MX2010009654A - Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos. - Google Patents

Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.

Info

Publication number
MX2010009654A
MX2010009654A MX2010009654A MX2010009654A MX2010009654A MX 2010009654 A MX2010009654 A MX 2010009654A MX 2010009654 A MX2010009654 A MX 2010009654A MX 2010009654 A MX2010009654 A MX 2010009654A MX 2010009654 A MX2010009654 A MX 2010009654A
Authority
MX
Mexico
Prior art keywords
metabolic disorders
treating metabolic
carboxylic acid
acid derivatives
derivatives useful
Prior art date
Application number
MX2010009654A
Other languages
English (en)
Inventor
Wang Shen
Julio C Medina
Jiwen Liu
Liusheng Zhu
Jonathan Houze
Yingcai Wang
Ming Yu
Paul J Dransfield
Vatee Pattaropong
Marc Vimolratana
Sean P Brown
Todd J Kohn
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2010009654A publication Critical patent/MX2010009654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención proporciona compuestos útiles, por ejemplo, para tratar trastornos metabólicos en un sujeto. Estos compuestos tienen la fórmula general I o la fórmula general III: (ver fórmula (I) y (II)) en donde las definiciones de las variables se proporcionan en la presente. La presente invención proporciona también composiciones que incluyen, y métodos para usar, los compuestos en la preparación de medicamentos y para tratar trastornos metabólicos tales como, por ejemplo, diabetes tipo (II).
MX2010009654A 2008-03-06 2009-03-04 Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos. MX2010009654A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6873308P 2008-03-06 2008-03-06
US19624908P 2008-10-15 2008-10-15
PCT/US2009/001435 WO2009111056A1 (en) 2008-03-06 2009-03-04 Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders

Publications (1)

Publication Number Publication Date
MX2010009654A true MX2010009654A (es) 2010-09-28

Family

ID=40810347

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009654A MX2010009654A (es) 2008-03-06 2009-03-04 Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.

Country Status (7)

Country Link
US (1) US8450522B2 (es)
EP (1) EP2260017A1 (es)
JP (1) JP2011515341A (es)
AU (1) AU2009220163B2 (es)
CA (1) CA2716352C (es)
MX (1) MX2010009654A (es)
WO (1) WO2009111056A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010123016A1 (ja) * 2009-04-22 2012-10-25 アステラス製薬株式会社 カルボン酸化合物
WO2011078371A1 (ja) 2009-12-25 2011-06-30 持田製薬株式会社 新規３－ヒドロキシ－５－アリールイソチアゾール誘導体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2526124T3 (es) * 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
BR112013027883A2 (pt) 2011-04-27 2017-08-08 Mochida Pharm Co Ltd novo derivado de 1-óxido de 3-hidroxiisotiazol
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2820005A1 (en) 2012-02-28 2015-01-07 Piramal Enterprises Limited Phenyl alkanoic acid derivatives as gpr agonists
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
AR096041A1 (es) 2013-04-17 2015-12-02 Piramal Entpr Ltd Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
CA2955071A1 (en) 2014-07-15 2016-01-21 Grunenthal Gmbh Substituted azaspiro(4.5)decane derivatives
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2016022448A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018130437A1 (de) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
AR111199A1 (es) * 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
WO2019099315A1 (en) 2017-11-16 2019-05-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
UA126458C2 (uk) 2018-02-13 2022-10-05 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
CA3093189A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
US20220305051A1 (en) * 2019-09-05 2022-09-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitrite formulations and uses thereof for the treatment of lung injury
CN113816818B (zh) * 2021-09-17 2023-07-25 哈尔滨工业大学（深圳） 一种铜催化不对称烯丙基烷基化反应方法及手性化合物

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE305216B (es) * 1965-09-17 1968-10-21 Astra Apotekarnes Kem Fab
FR2359135A1 (fr) 1976-07-22 1978-02-17 Hexachimie Nouvelles phenoxyhydroxypropylamines, procede pour les preparer et leur application en therapeutique
US4760089A (en) * 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors
DK303887A (da) 1986-06-19 1987-12-20 Smithkline Beckman Corp Dopamin-beta-hydroxylaseinhibitorer og fremgangsmaade til fremstilling deraf
GB8917069D0 (en) 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
DE4019307A1 (de) * 1990-06-16 1991-12-19 Bayer Ag 2-methoximinocarbonsaeureester
EP0641204B1 (en) 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers and thioethers of 4-aza-steroids
ATE198601T1 (de) 1992-05-20 2001-01-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
HUT73813A (en) 1993-06-30 1996-09-30 Wellcome Found Anti-athero-sclerotic diaryl compounds, process to prepare them and pharmaceutical compositions contg. them
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
EP0827495A4 (en) * 1995-07-14 1998-11-04 Smithkline Beecham Corp SUBSTITUTED PENT-4-IN ACIDS
US5795900A (en) 1995-10-03 1998-08-18 Abbott Laboratories Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
JPH10316641A (ja) 1997-03-14 1998-12-02 Sankyo Co Ltd カルボン酸誘導体
WO1999011255A1 (fr) 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
US6645939B1 (en) * 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
EP1067109B1 (en) * 1998-03-10 2009-12-09 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19941567A1 (de) 1998-09-05 2000-04-20 Merck Patent Gmbh Neue flüssigkristalline Verbindungen
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
DE60009480T2 (de) * 1999-05-05 2005-09-01 Aventis Pharma Ltd., West Malling Harnstoffe als modulatoren der zelladhäsion
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
JP2001242165A (ja) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd 採血用試薬
JP2002003368A (ja) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk 経皮吸収又は経粘膜吸収用の製剤
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
GB0031527D0 (en) 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
CA2433573A1 (en) * 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
CZ20033328A3 (cs) 2001-06-07 2004-06-16 Eli Lilly And Company Modulátory receptorů aktivovaných proliferátory peroxisomů (PPAR)
KR100948278B1 (ko) * 2002-02-07 2010-03-18 히토시 엔도 방향족 아미노산 유도체 및 의약 조성물
DE60332320D1 (de) * 2002-02-14 2010-06-10 Takeda Pharmaceutical Neues screening-verfahren
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US6906406B2 (en) * 2002-12-19 2005-06-14 Freescale Semiconductor, Inc. Multiple dice package
WO2004092117A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
ES2558761T3 (es) * 2003-05-19 2016-02-08 Novartis Ag Compuestos y composiciones inmunosupresores
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CN1894225A (zh) 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
RU2006126978A (ru) * 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US7326732B2 (en) * 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
ES2433466T3 (es) * 2004-02-27 2013-12-11 Amgen, Inc Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
JP2007269630A (ja) 2004-06-23 2007-10-18 Toudai Tlo Ltd インスリン分泌促進剤
US20060003344A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
DE102005045849A1 (de) 2004-10-07 2006-04-20 Merck Patent Gmbh Verfahren zur Herstellung von benzokondensierten Sauerstoffheterocyclen
EP1831190A2 (de) * 2004-10-07 2007-09-12 Merck Patent GmbH Chroman-derivate sowie ihre verwendung in flüssigkristallinen medien
US20080090865A1 (en) 2005-01-28 2008-04-17 Min Ge Antidiabetic Bicyclic Compounds
EP1846379B1 (en) 2005-01-31 2009-08-19 Merck & Co., Inc. Antidiabetic bicyclic compounds
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
AU2006291234A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
JP2007262009A (ja) * 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
DE102006021874B4 (de) 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20080069A1 (es) * 2006-05-15 2008-02-22 Merck & Co Inc Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40)
KR101703465B1 (ko) 2006-06-23 2017-02-06 메르크 파텐트 게엠베하 메소제닉 화합물, 액정 매질 및 액정 디스플레이
CN102731451B (zh) * 2006-06-27 2015-07-29 武田药品工业株式会社 稠环化合物
AU2007292816B2 (en) * 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US7714008B2 (en) * 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
CA2683751C (en) * 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
AU2008311355B2 (en) * 2007-10-10 2012-01-19 Amgen Inc. Substituted biphenyl GPR40 modulators

Also Published As

Publication number Publication date
AU2009220163B2 (en) 2011-10-06
AU2009220163A1 (en) 2009-09-11
US8450522B2 (en) 2013-05-28
JP2011515341A (ja) 2011-05-19
US20100298367A1 (en) 2010-11-25
EP2260017A1 (en) 2010-12-15
CA2716352C (en) 2013-05-28
WO2009111056A1 (en) 2009-09-11
CA2716352A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
WO2010045258A3 (en) Spirocyclic gpr40 modulators
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
MX2010010135A (es) Derivados de hidroximoil-tetrazol fungicidas.
TW200745003A (en) Novel compounds
IN2012DN01233A (es)
MX2012015252A (es) Estimuladores de sgc.
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
TN2012000530A1 (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
TN2009000509A1 (en) Pyrazole carboxylic acid amides useful as microbiocides
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
WO2011082266A3 (en) Substituted heterocyclic compounds
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds
MX2010007392A (es) Antagonistas de trpa1.
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
MX2010007391A (es) Antagonistas de trpa1.
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
WO2010067078A8 (en) 3,6-disubstituted xanthylium salts
WO2009153178A3 (en) Aryl ketone as mri
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
MX342947B (es) Tratamiento de diabetes tipo 2.

Legal Events

Date Code Title Description
FG Grant or registration